Arcturus Therapeutics (Mfg)
San Diego, CA
Hybrid — also manufactures internal programs
No confirmed program data — ClinicalTrials.gov verification pending
· Last scored 2026-09-07
65.5
Signal Score
○ FDA Inspections
○ Clinical Trials
✓ SEC Filings (13)
○ Press
○ EMA GMP
○ MHRA GMP
Quick Facts: Arcturus Therapeutics (Mfg)
- Signal Score
- 65.5/100 (as of 2026-09-07)
- Quality Compliance
- Assessment pending
- Headquarters
- San Diego, CA
- Modalities
- mRNA
- Active Programs
- Data pending
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Arcturus Therapeutics (Mfg)
Hybrid developer + CDMO.
Signal Score & Pillar Breakdown
Scores are being republished.
Scores are being republished under methodology v3.3. The score shown is the last complete v3.2 result, which is also what directory listings and search results show. A pillar breakdown is not shown because the current one is computed under v3.3 and would not explain a v3.2 score. Regulatory evidence below is current.
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesmRNA
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
69.0
13 SEC filings with industry mentions on record
SEC Filings13 with industry mentions
Capacity
62.0
Profile-based capacity assessment
Financial Intelligence
"Optimized conditions identified by these small-scale models are applied to the cGMP manufacturing processes."
"The success of CAR-T cells in immuno-oncology has led to a growing number of therapies utilizing other immune cell types engineered to express a variety of immunomodulatory molecules."
"With such collaborations, we have established an Integrated Global Supply Chain Network with our primary and secondary sourcing contract development & manufacturing organizations (CDMOs) based in the United States, EU and Asia for producing critical raw materials, drug substance, and packaged finished product."
"Later, we published the results of Phase 3c part of the study, comparing the immunogenicity and efficacy of ARCT-154 and licensed adenoviral vector vaccine ChAdOx-1S, demonstrating higher immunogenicity and relative vaccine efficacy (19.8% (95% CI: 4.0–33.0)) of ARCT-154 compared to ChAdOx-1S (
https://pmc.ncbi.nlm.nih.gov/articles/PMC11585660/
)."
"Optimized conditions identified by these small-scale models are applied to the cGMP manufacturing processes."
"The success of CAR-T cells in immuno-oncology has led to a growing number of therapies utilizing other immune cell types engineered to express a variety of immunomodulatory molecules."
"With such collaborations we have established an Integrated Global Supply Chain Network with our primary and secondary sourcing contract development & manufacturing organizations (CDMOs) based in the United States, EU and Asia for producing critical raw materials, drug substance, and packaged finished product."
"With such collaborations we have established an Integrated Global Supply Chain Network with our primary and secondary sourcing contract development & manufacturing organizations (CDMOs) based in the United States, EU and Asia for producing critical raw materials, drug substance, and packaged finished product."
"With such collaborations we have established an Integrated Global Supply Chain Network with our primary and secondary sourcing contract development & manufacturing organizations (CDMOs) based in the United States, EU and Asia for producing critical raw materials, drug substance, and packaged finished product."
"The increases were offset by a $3.5 million decrease in discovery technologies expenses, a $2.1 million decrease in COVID expenses primarily caused by fewer contract manufacturing costs and a $1.9 million decrease in OTC expenses."
Source: SEC EDGAR · Retrieved Oct 07, 2026
Frequently Asked Questions About Arcturus Therapeutics (Mfg)
What is Arcturus Therapeutics (Mfg)'s CDMO Signal Score?
Arcturus Therapeutics (Mfg) has a Signal Score of 66/100, based on quality, operations, financial stability, and capacity data.
Evaluating Arcturus Therapeutics (Mfg) for a manufacturing program?
Use the free AI matchmaker to compare Arcturus Therapeutics (Mfg) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Wacker Biotech
Jena, DE · Amsterdam, NL · San Diego, CA
Signal Score: 81.6
Recombinant Protein, Plasmid DNA, mRNA
National Resilience
San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
Signal Score: 74.5
mRNA, Gene Therapy, Cell Therapy, Lentiviral
TriLink BioTechnologies
San Diego, CA
Signal Score: 71.0
mRNA, Oligonucleotide
Pfizer CentreOne
Kalamazoo, MI · McPherson, KS
Signal Score: 91.5
Biologics, mRNA
ReciBioPharm
Keele, UK · Sodertalje, SE
Signal Score: 88.0
AAV, Lentiviral, Plasmid, mRNA